Search results for "Deep vein"

showing 10 items of 96 documents

Acute deep vein thrombosis suppresses peripheral T cell effector function

2018

0301 basic medicinePathologymedicine.medical_specialtyEffectorbusiness.industryDeep veinT cellHematologymedicine.diseaseThrombosisPeripheral03 medical and health sciencesVenous thrombosis030104 developmental biology0302 clinical medicinemedicine.anatomical_structureImmunophenotyping030220 oncology & carcinogenesismedicinebusinessFunction (biology)British Journal of Haematology
researchProduct

Comparison of Unfractionated Versus Low Molecular Weight Heparin for Deep Vein Thrombosis Prophylaxis During Breast and Pelvic Cancer Surgery: Effica…

1998

In a prospective, double-blind randomized trial the efficacy and safety of low molecular weight heparin and un fractionated heparin were compared for the prevention of post operative deep vein thrombosis in patients undergoing major surgery for breast and pelvic cancer. Three hundred fifty-eight patients were randomly allocated to the two treatment groups. Thirty-four of these were excluded from the study. Of the re maining 324 patients, 164 received 5000 IU unfractionated heparin three times daily and 160 received 3000 anti-Xa units of low molecular weight heparin once daily. Treatment was started 2 to 5 hours preoperatively and continued for 7 days. The occurrence of deep vein thrombosis…

0301 basic medicinemedicine.medical_specialtymedicine.drug_classDeep veinVenographyLow molecular weight heparin030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawMedicinePlethysmographmedicine.diagnostic_testbusiness.industryHematologyGeneral MedicineHeparinmedicine.diseaseThrombosisSurgery030104 developmental biologymedicine.anatomical_structureRelative riskAnesthesiabusinessmedicine.drugClinical and Applied Thrombosis/Hemostasis
researchProduct

Coronavirus Disease 2019–Associated Coagulopathy

2021

Patients with the severe form of coronavirus disease 2019 (COVID-19) have been frequently found to suffer from both arterial and venous thrombotic events due to the perpetuation of a hypercoagulable state. This phenomenon, termed COVID-19-associated coagulopathy (CC), is now considered a major component of the pathophysiology of this novel infectious disease, leading to widespread thrombosis. While at first, the vascular insults may be limited to the pulmonary microvasculature, as the disease progresses, systemic involvement occurs, culminating in distant organ thrombosis and multi-organ dysfunction syndrome. In this review article, we discuss recent insights into the pathophysiologic mecha…

ARDSPAI-1 Plasminogen Activator Inhibitor 1VTE venous thromboembolismDiseaseReview030204 cardiovascular system & hematologyCoronavirus Disease 20190302 clinical medicineCoagulopathy030212 general & internal medicineDIC disseminated intravascular coagulationDisseminated intravascular coagulationCOVID-19 Coronavirus disease 2019DVT deep vein thrombosisGeneral MedicineBlood Coagulation DisordersThrombosisICU intensive care unitTMA thrombotic microangiopathyDisease ProgressionCoronavirus Disease 2019 COVID-19 CoagulopathyVWF von Willebrand factormedicine.medical_specialtyThrombotic microangiopathyACE2 angiotensin-converting enzyme 2SARS-CoV-2 severe acute respiratory syndrome coronavirus 203 medical and health sciencesmedicineCoagulopathyHumansIntensive care medicineLY30 lysis at 30 minutesARDS acute respiratory distress syndromeHemostasisNO nitric oxideCoagulationbusiness.industrySARS-CoV-2COVID-19Thrombosismedicine.diseasetPA tissue plasminogen activatorReview articleIL interleukinCoronavirusVascular DisorderPE pulmonary embolismTF tissue factorbusinessCC COVID-associated coagulopathyMayo Clinic Proceedings
researchProduct

Influence of lipids and obesity on haemorheological parameters in patients with deep vein thrombosis.

2007

It is not well established whether haemorheological alterations constitute independent risk factors for deep vein thrombosis (DVT).We have determined in 149 DVT patients and in 185 control subjects the body mass index (BMI), the haemorheological profile: blood viscosity (BV), plasma viscosity (PV), fibrinogen (Fg), erythrocyte aggregation (EA), erythrocyte deformability (ED) and plasma lipids. In the crude analysis BMI, Fg, PV, EA, triglycerides (TG) and ApoB were statistically higher and HDL cholesterol (HDL-Chol) statistically lower in DVT patients than in controls. No differences in BV and ED were observed.After BMI adjustment, Fg, PV and EA remained statistically higher in DVT cases tha…

AdultErythrocyte AggregationMalemedicine.medical_specialtyTime FactorsDeep veinBlood viscosityHyperlipidemiasFibrinogenGastroenterologyRisk AssessmentBody Mass IndexDeep vein thrombosis; Lipids; Obesity; HaemorheologyRisk FactorsInternal medicineDeep vein thrombosisErythrocyte DeformabilityOdds RatioMedicineHumanscardiovascular diseasesObesityRisk factorTriglyceridesUNESCO::CIENCIAS MÉDICAS ::Patología::TrombosisVenous Thrombosisbusiness.industryFibrinogenHematologyOdds ratioMiddle Agedmedicine.diseaseBlood ViscosityThrombosisLipidsSurgeryHaemorheologymedicine.anatomical_structureCholesterolCase-Control StudiesHemorheologyHemorheologyFemalebusinessBody mass index:CIENCIAS MÉDICAS ::Patología::Trombosis [UNESCO]medicine.drugThrombosis and haemostasis
researchProduct

Blood rheology during chemotherapy in patients with ovarian cancer.

1998

The use of platinum based chemotherapy in ovarian malignancy and other cancer types is known to be associated with deep vein thrombosis. In a prospective study of 47 patients with ovarian cancer of International Federation of Gynecology and Obstetrics stage Ib-IV, serial rheological parameters were determined (plasma viscosity, red blood cell aggregation under conditions of stasis and low shear) in addition to hemoglobin, hematocrit, leukocytes, platelets, and fibrinogen. At the same time the incidence of deep vein thrombosis was recorded before, during six cycles of first line cisplatinum/epirubicin/cyclophosphamide chemotherapy, and 2 months thereafter (two-months check-up). Only six pati…

AdultErythrocyte Aggregationmedicine.medical_specialtymedicine.drug_classDeep veinBlood viscosityVenographyLow molecular weight heparinAntineoplastic AgentsHematocritGastroenterologyHemoglobinsLeukocyte CountInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesVeinCyclophosphamideAgedEpirubicinOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryPlatelet CountFibrinogenHematologyHeparin Low-Molecular-WeightMiddle AgedThrombophlebitismedicine.diseaseBlood ViscosityThrombosisSurgerymedicine.anatomical_structureHematocritHemorheologyFemaleCisplatinbusinessEpirubicinmedicine.drugThrombosis research
researchProduct

Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study

2021

Background Thrombosis and pulmonary embolism appear to be major causes of mortality in hospitalized coronavirus disease 2019 (COVID-19) patients. However, few studies have focused on the incidence of venous thromboembolism (VTE) after hospitalization for COVID-19. Methods In this multi-center study, we followed 1529 COVID-19 patients for at least 45 days after hospital discharge, who underwent routine telephone follow-up. In case of signs or symptoms of pulmonary embolism (PE) or deep vein thrombosis (DVT), they were invited for an in-hospital visit with a pulmonologist. The primary outcome was symptomatic VTE within 45 days of hospital discharge. Results Of 1529 COVID-19 patients discharge…

AdultMaleARDSmedicine.medical_specialtyTime FactorsDeep veinIran030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsFull Length ArticleInternal medicinemedicineHumansProspective Studiescardiovascular diseasesMyocardial infarctionThromboprophylaxisStrokeAgedAged 80 and overVenous Thrombosisbusiness.industryIncidenceIncidence (epidemiology)COVID-19Venous ThromboembolismHematologyMiddle Agedmedicine.diseaseThrombosisPatient DischargePulmonary embolismHospitalizationmedicine.anatomical_structure030220 oncology & carcinogenesisHeart failureFemaleCohort studyPulmonary EmbolismbusinessThrombosis Research
researchProduct

Deep Venous Thrombosis: Leukocyte Rheology at Baseline and after in vitro Activation

2001

We evaluated leukocyte rheology, expressed as leukocyte filtration, polymorphonuclear (PMN) membrane fluidity and cytosolic Ca<sup>2+</sup> concentration in subjects with acute deep venous leg thrombosis (DVT). In 14 subjects with leg DVT we examined the leukocyte filtration [unfractionated, mononuclear cells (MN), PMNs], PMN membrane fluidity and PMN cytosolic Ca<sup>2+</sup> concentration. Subsequently, we evaluated the same PMN variables after in vitro chemotactic activation with 4-phorbol-12-myristate-13-acetate. At baseline, we observed a significant difference in the filtration of unfractionated and MNs and in PMN cytosolic Ca<sup>2+</sup> concentra…

AdultMalePathologymedicine.medical_specialtyMembrane FluidityNeutrophileDeep veinBiologyGranulocytePathogenesisPhysiology (medical)LeukocytesmedicineMembrane fluidityHumansCells CulturedAgedVascular diseaseHematologyMiddle AgedThrombophlebitismedicine.diseaseThrombosisChemotaxis LeukocyteVenous thrombosismedicine.anatomical_structureImmunologyCalciumFemaleRheologyPathophysiology of Haemostasis and Thrombosis
researchProduct

Thromboembolic events in Fabry disease and the impact of factor V Leiden

2015

Although several reports suggest an increased thromboembolic event rate, especially regarding strokes and TIAs at early age in patients with Fabry disease (FD), the risk for patients with FD to experience these events, the clinical relevance of additional risk factors including the concurrence of factor V Leiden (FVL), and the benefit of enzyme replacement therapy (ERT) regarding these events remain unclear.Three hundred four consecutively recruited patients with FD were evaluated for their lifetime occurrence of thromboembolic events such as stroke, TIA, deep vein thrombosis, and pulmonary embolism. The thromboembolic risk was determined in patients with FD and concurrent FVL, and the impa…

AdultMaleRiskmedicine.medical_specialtyAdolescentEndocrinology Diabetes and MetabolismDeep veinComorbidityBiochemistryYoung AdultEndocrinologyInternal medicineGeneticsmedicineFactor V LeidenHumansEnzyme Replacement TherapyChildMolecular BiologyStrokeAgedAged 80 and overVenous Thrombosisbusiness.industryHazard ratioFactor VEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseThrombosisComorbidityPulmonary embolismStrokemedicine.anatomical_structureIschemic Attack TransientChild PreschoolFabry DiseaseFemaleNeurology (clinical)Pulmonary EmbolismbusinessNeurology
researchProduct

Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet's disease and deep vein thrombosis

2004

OBJECTIVE: To evaluate the frequency and type of vascular lesions and to study the association of factor V gene G1691A (Leiden) and prothrombin gene G20210A polymorphisms with venous thrombosis in Italian patients with Behçet's disease (BD). METHODS: Included were 118 consecutive Italian BD patients followed over a 3-year period (1997-1999) who satisfied the International Study Group criteria for BD. The control group consisted of 132 healthy Italian blood donors. All BD patients and controls were genotyped by polymerase chain reaction and allele-specific restriction enzyme techniques for factor V Leiden and prothrombin gene G20210A polymorphisms. RESULTS: Vascular lesions were observed in …

AdultMaleVenous ThrombosisFactor V Leiden mutation Prothrombin G20210A mutationAdolescentGenotypeBehcet SyndromeFactor VMiddle AgedBehc ̧et’s disease; Deep vein thrombosis; Factor V Leiden mutation Prothrombin G20210A mutationAdolescent; Adult; Behcet Syndrome; Factor V; Female; Gene Frequency; Genotype; Humans; Italy; Male; Middle Aged; Prothrombin; Risk Factors; Venous Thrombosis; Point MutationGene FrequencyItalyDeep vein thrombosiRisk FactorsFactor V Leiden mutationHumansPoint MutationFemaleProthrombinProthrombin G20210A mutationBehcet’s disease
researchProduct

Sex-specific differences in the distal versus proximal presenting location of acute deep vein thrombosis

2018

Abstract Background and aims Women present with pulmonary embolism (PE) more often than men, while the opposite is true for proximal deep vein thrombosis (DVT). We investigated whether sex-specific differences exist in the presenting location of acute symptomatic DVT among patients without concomitant PE. Methods We tested our hypothesis in a meta-analysis of studies selected by systematically reviewing PubMed, Embase, and the grey literature. Thereafter, we analysed data of a single-center cohort including patients with first isolated acute DVT to assess the additional impact of age and provoking risk factors on the presenting location of DVT. Results We identified 7 studies for a total of…

AdultMalemedicine.medical_specialtyAdolescentDeep vein030204 cardiovascular system & hematologyYoung Adult03 medical and health sciencesSex Factors0302 clinical medicineRecurrenceRisk FactorsInternal medicineHumansMedicinecardiovascular diseasesAgedVenous Thrombosisbusiness.industryHematologyOdds ratioMiddle Agedmedicine.diseaseThrombosisSex specificPulmonary embolismmedicine.anatomical_structure030220 oncology & carcinogenesisConcomitantAcute DiseaseCohortFemalebusinessCohort studyThrombosis Research
researchProduct